+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 80Years
All Genders
ID07380919

Study of Ranolazine to Protect Small Heart Vessels in Adults With ST-Elevation Heart Attack and Multiple Blocked Arteries

Led by Federico II University · Updated on 2026-03-11

100

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of inhibiting late INa current with ranolazine to improve coronary microcirculation in patients who have acute myocardial infarction heart attack with multivessel disease. This Phase IIb open-label study aims to compare ranolazine plus standard therapy against standard therapy alone in preserving coronary microcirculation after successful primary percutaneous coronary intervention pPCI. The study also investigates various secondary outcomes such as coronary microvascular dysfunction CMD, infarct size, endothelial function, major cardiovascular events, angina symptoms, and quality of life. Participants will be randomly assigned to one of two groups the experimental group will receive oral ranolazine starting at 500 mg twice daily, increased to 750 mg twice daily from 7 days after pPCI to up to 6 weeks the control group will receive standard therapy without ranolazine. Coronary microcirculation will be assessed invasively or by angiography-based Index of Microcirculatory Resistance IMRangioIMR at baseline after pPCI and at follow-up during staged PCI of non-culprit lesions, either within 5 days or up to 6 weeks. The study is conducted at multiple centers and follows patients for up to 8 weeks. Participants will undergo coronary microcirculation measurements at two time points along with cardiac magnetic resonance imaging to assess infarct size. Additional assessments include evaluations of endothelial function using EndoPAT, angina symptoms through SAQ7, and quality of life using EuroQoL questionnaires. The study monitors major adverse cardiovascular events MACE, periprocedural myocardial infarction, and other clinical outcomes. The total participation duration lasts approximately 6 to 8 weeks after initial pPCI with close clinical follow-up during this period.

CONDITIONS

Brief Title

Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study

Research Team

L

Luigi Di Serafino, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here